Quality Egg Production Through Improved Nutrition Management

reading time
Article | 03.07.2019

It is widely recognised that eggs are an important foodstuff as they are a source of high quality protein, vitamins and minerals. Additionally, eggs are one of the most widely available and easily affordable animal products.

However, one of the major challenges in their production is the move towards a longer laying period for the hen.

The current production period has been extended to more than 85 weeks of age by selecting on egg persistency, egg shell quality and internal egg quality in hens at older ages. The aim is to push that number up to an ideal minimum of 100 weeks, under commercial conditions. 

Increased calcium requirement

In physiolocial terms this means the hen is producing 26kg of eggs over those 100 weeks, which is about 14-fold her bodyweight. To achieve this, around 3kg of egg shell is needed, or more than 1kg of calcium - severly challenging the metabolism and homeostasis of the hen.

At the moment, lower shell quality is the main reason to terminate a layer flock, rather than persistency of egg production. Shell formation especially challenges the calcium metabolism in the hens. 

On average, eggshell consists of 96% calcium carbonate and 4% organic matrix: therefore, each egg requires about 2.0-2.5g of calcium for its shell. To satisfy this need, calcium provision heavily depends on intestinal absorption from the feed, with the skeleton acting as a secondary source of the mineral during the dark hours of the day, when intestinal absorption has ceased. The metabolised form of vitamin D3 regulates the interaction between the two. 

Managing this regulation mechanism is an option to influence calcium uptake, and thus egg shell quality. Vitamin D3 itself is initially absorbed from the intestine in association with fats, requiring the presence of bile salts for absorption. It is then hydrolysed in the liver, forming 25-OHvitD3. A second hydrolisation of this metabolite is needed before it can become an active player in calcium regulation.

This step is precisely regulated in the kidneys, thus providing the active metabolite of the vitamin. This active hormonal form, 1,25-OHvitD3, regulates the intestinal absorption of calcium, bone homeostasis, calcium release from bone and the reabsorption of the mineral in the kidneys. However, this cascade heavily depends on the efficiency and health of the liver: without it, 25-OHvitD3 cannot be produced in sufficient quantities, an example is fatty liver syndrome, frequently seen in aged birds.

The evident risk is that a vitamin D3 deficiency develops, additionally derailing proper calcium regulation even before the first precursor of the final active vitamin D3 metabolite is formed.

Direct supplementation

Direct supplementation of dietary 25-OHvitD3 has been proposed as a solution, aiming to improve egg shell quality by positively impacting calcium regulation. To support this, different studies have been conducted to show the benefits of a new 25-OHvitD3 form, Bio D®, produced by fermentation. The results in 75 week old layers (Lohmann Brown) is one of the studies and summarised in Table 1.

Table 1. Summary of Bio D® in 75 week old layers

Partly replacing vitamin D3 by this 25-OHvitD3 (of fermentation origin) decreased the number of broken eggs as a result of a stronger egg shell. At the same time, bone strength increased parallel with shell quality, so that the animal's welfare was secured.

These results indicate the value of supplementing this new form of 25-OHvitD3 directly into the feed, both in terms of positively impacting egg shell quality as well as improving bone mineralisation. 

Maintaining the layer hen industry's goal of extending laying cycles with minimal loss of egg quality in mind, it is clear what key role this nutrient should play in the future.

 

This article originally appeared in International Poultry Production, Volume 27 Number 6.

global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us

Huvepharma®

Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region or click to see all products and services.

Africa

Asia

Europe

North America

Oceania

South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.

Europe

United States

Click here to visit the local website or close this popup to stay on the global website.

top
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now

By continuing to view this website you agree to the Huvepharma® cookie statement. Read more Agree